The discovery could pave the way for a groundbreaking RNA-based multi-cancer treatment. Alternative RNA splicing functions ...

LCGC International spoke with Daniel Meston and Dwight Stoll from Gustavus Adolphus College in St. Peter, Minnesota, USA, ...

Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), ”), a leader in RNA-based therapeutics, announced today the successful completion of a Phase 1 clinical trial ...

ELRIG meeting on Therapeutic Oligonucleotides brings together esteemed scientists from academia, industry, and other members ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...

Natural "off switch" could slow or even reverse the growth of aggressive tumors.

The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...

Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) had its price objective lowered by JPMorgan Chase & Co. from $47.00 to $45.00 in a research report released on Monday,Benzinga reports. JPMorgan Chase ...

Alternative splicing (AS) of pre-mRNA plays a crucial role in tissue-specific gene regulation, with disease implications due to splicing defects. Predicting and manipulating AS can therefore uncover ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...

The US biotech has just reported phase 2 trial results with the small, interfering RNA (siRNA ... of Ionis – which are developing an antisense-based candidate called pelacarsen (formerly ...